WO1995009006A1 - Monoglyceride/lactate ester permeation enhancer - Google Patents
Monoglyceride/lactate ester permeation enhancer Download PDFInfo
- Publication number
- WO1995009006A1 WO1995009006A1 PCT/US1994/011120 US9411120W WO9509006A1 WO 1995009006 A1 WO1995009006 A1 WO 1995009006A1 US 9411120 W US9411120 W US 9411120W WO 9509006 A1 WO9509006 A1 WO 9509006A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drug
- lactate
- mixture
- reservoir
- skin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU79249/94A AU679793B2 (en) | 1993-09-29 | 1994-09-29 | Monoglyceride/lactate ester permeation enhancer |
DE69420419T DE69420419T2 (en) | 1993-09-29 | 1994-09-29 | SKIN PERMEABILITY HIGHER CONSISTING OF MONOGLYCERIDE / LACTATE ESTERS |
KR1019960701610A KR960704578A (en) | 1993-09-29 | 1994-09-29 | Monoglyceride / Lactate Ester Permeation Enhancer |
EP94929976A EP0721348B1 (en) | 1993-09-29 | 1994-09-29 | Monoglyceride/lactate ester permeation enhancer |
JP51047695A JP3688293B2 (en) | 1993-09-29 | 1994-09-29 | Monoglyceride / lactic acid ester permeation enhancer |
US08/637,678 US5750137A (en) | 1993-09-29 | 1994-09-29 | Monoglyceride/lactate ester permeation enhancer |
ZA947700A ZA947700B (en) | 1994-09-29 | 1994-10-03 | Monoglyceride/lactate ester permeation enhancer |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12949493A | 1993-09-29 | 1993-09-29 | |
US129,494 | 1993-09-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995009006A1 true WO1995009006A1 (en) | 1995-04-06 |
Family
ID=22440240
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/011226 WO1995009007A1 (en) | 1993-09-29 | 1994-09-29 | Monoglyceride/lactate ester permeation enhancer for oxybutynin |
PCT/US1994/011120 WO1995009006A1 (en) | 1993-09-29 | 1994-09-29 | Monoglyceride/lactate ester permeation enhancer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/011226 WO1995009007A1 (en) | 1993-09-29 | 1994-09-29 | Monoglyceride/lactate ester permeation enhancer for oxybutynin |
Country Status (10)
Country | Link |
---|---|
US (3) | US5750137A (en) |
EP (2) | EP0721349A1 (en) |
JP (3) | JP3688293B2 (en) |
KR (2) | KR960704578A (en) |
AT (1) | ATE183926T1 (en) |
AU (2) | AU679794B2 (en) |
CA (2) | CA2165802A1 (en) |
DE (1) | DE69420419T2 (en) |
NZ (2) | NZ274711A (en) |
WO (2) | WO1995009007A1 (en) |
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996010429A2 (en) * | 1994-09-29 | 1996-04-11 | Alza Corporation | Improved transdermal device having decreased delamination |
WO1996037231A1 (en) * | 1995-05-26 | 1996-11-28 | Alza Corporation | Skin permeation enhancer compositions using acyl lactylates |
FR2735027A1 (en) * | 1995-06-07 | 1996-12-13 | Alza Corp | Compsns. for acceleration of transdermal passage of active materials |
WO1996040259A2 (en) * | 1995-06-07 | 1996-12-19 | Alza Corporation | Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate |
WO1997024148A1 (en) * | 1995-12-29 | 1997-07-10 | Cygnus, Inc. | Systems and methods for the transdermal administration of androgenic agents |
WO1997039743A1 (en) * | 1996-04-24 | 1997-10-30 | Rutgers, The State University Of New Jersey | Transdermal contraceptive delivery system |
WO1998000118A2 (en) * | 1996-07-03 | 1998-01-08 | Alza Corporation | Drug delivery devices and process of manufacture |
WO1998010770A1 (en) * | 1996-09-11 | 1998-03-19 | Tillotts Pharma Ag | Oral compositions containing fluocinonide |
US5925629A (en) * | 1997-10-28 | 1999-07-20 | Vivus, Incorporated | Transurethral administration of androgenic agents for the treatment of erectile dysfunction |
US6004578A (en) * | 1996-10-24 | 1999-12-21 | Alza Corporation | Permeation enhances for transdermal drug delivery compositions, devices and methods |
US6007837A (en) * | 1996-07-03 | 1999-12-28 | Alza Corporation | Drug delivery devices and process of manufacture |
US6174545B1 (en) | 1997-07-01 | 2001-01-16 | Alza Corporation | Drug delivery devices and process of manufacture |
US6203817B1 (en) | 1997-02-19 | 2001-03-20 | Alza Corporation | Reduction of skin reactions caused by transdermal drug delivery |
US6267984B1 (en) | 1997-12-22 | 2001-07-31 | Alza Corporation | Skin permeation enhancer compositions comprising a monoglyceride and ethyl palmitate |
US6512010B1 (en) | 1996-07-15 | 2003-01-28 | Alza Corporation | Formulations for the administration of fluoxetine |
US6960353B2 (en) | 1998-07-24 | 2005-11-01 | Alza Corporation | Formulations for the transdermal administration of fenoldopam |
EP1666026B2 (en) † | 1999-02-08 | 2015-02-25 | Intarcia Therapeutics, Inc | Non-aqueous single phase biocompatible viscous vehicles and methods for preparing the same |
US8992961B2 (en) | 1999-02-08 | 2015-03-31 | Intarcia Therapeutics, Inc. | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
US9006461B2 (en) | 2013-02-28 | 2015-04-14 | Dermira, Inc. | Crystalline glycopyrrolate tosylate |
US9006462B2 (en) | 2013-02-28 | 2015-04-14 | Dermira, Inc. | Glycopyrrolate salts |
US9526763B2 (en) | 2005-02-03 | 2016-12-27 | Intarcia Therapeutics Inc. | Solvent/polymer solutions as suspension vehicles |
US9539200B2 (en) | 2005-02-03 | 2017-01-10 | Intarcia Therapeutics Inc. | Two-piece, internal-channel osmotic delivery system flow modulator |
US9572889B2 (en) | 2008-02-13 | 2017-02-21 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
US9610278B2 (en) | 2013-02-28 | 2017-04-04 | Dermira, Inc. | Glycopyrrolate salts |
US9682127B2 (en) | 2005-02-03 | 2017-06-20 | Intarcia Therapeutics, Inc. | Osmotic delivery device comprising an insulinotropic peptide and uses thereof |
US9724293B2 (en) | 2003-11-17 | 2017-08-08 | Intarcia Therapeutics, Inc. | Methods of manufacturing viscous liquid pharmaceutical formulations |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
US10028858B2 (en) | 2011-07-11 | 2018-07-24 | Medicines360 | Intrauterine systems, IUD insertion devices, and related methods and kits therefor |
USD835783S1 (en) | 2016-06-02 | 2018-12-11 | Intarcia Therapeutics, Inc. | Implant placement guide |
US10159714B2 (en) | 2011-02-16 | 2018-12-25 | Intarcia Therapeutics, Inc. | Compositions, devices and methods of use thereof for the treatment of cancers |
US10231923B2 (en) | 2009-09-28 | 2019-03-19 | Intarcia Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
US10501517B2 (en) | 2016-05-16 | 2019-12-10 | Intarcia Therapeutics, Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
US10527170B2 (en) | 2006-08-09 | 2020-01-07 | Intarcia Therapeutics, Inc. | Osmotic delivery systems and piston assemblies for use therein |
US10835580B2 (en) | 2017-01-03 | 2020-11-17 | Intarcia Therapeutics, Inc. | Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug |
US10925639B2 (en) | 2015-06-03 | 2021-02-23 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
Families Citing this family (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5736577A (en) * | 1995-01-31 | 1998-04-07 | Sepracor, Inc. | Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin |
ATE149349T1 (en) * | 1993-06-25 | 1997-03-15 | Alza Corp | INCORPORATING A POLY-N-VINYLAMIDE INTO A TRANSDERMAL SYSTEM |
CA2165802A1 (en) * | 1993-09-29 | 1995-04-06 | Eun Soo Lee | Monoglyceride/lactate ester permeation enhancer for oxybutynin |
US5677346A (en) * | 1995-01-31 | 1997-10-14 | Sepracor, Inc. | Treating urinary incontinence using (S)-desethyloxybutynin |
US5674895A (en) * | 1995-05-22 | 1997-10-07 | Alza Corporation | Dosage form comprising oxybutynin |
US6028057A (en) * | 1998-02-19 | 2000-02-22 | Thorn Bioscience, Llc | Regulation of estrus and ovulation in gilts |
DE19812413C1 (en) * | 1998-03-20 | 1999-06-10 | Sanol Arznei Schwarz Gmbh | Transdermal therapeutic system for administration of oxybutynin |
US6096332A (en) | 1998-06-30 | 2000-08-01 | Mcneil-Ppc, Inc. | Adding pharmaceutically active compounds to substrates |
WO2000064434A1 (en) * | 1999-04-26 | 2000-11-02 | Lead Chemical Co., Ltd. | Percutaneous preparations containing oxybutynin |
WO2000064528A1 (en) * | 1999-04-28 | 2000-11-02 | Situs Corporation | Drug delivery system |
AU767877B2 (en) | 1999-05-20 | 2003-11-27 | Sepracor, Inc. | Methods for treatment of asthma using S-oxybutynin |
US6787531B1 (en) * | 1999-08-31 | 2004-09-07 | Schering Ag | Pharmaceutical composition for use as a contraceptive |
IL149655A0 (en) * | 1999-11-24 | 2002-11-10 | Agile Therapeutics Inc | Improved transdermal contraceptive delivery system and process |
US7045145B1 (en) | 1999-11-24 | 2006-05-16 | Agile Therapeutics, Inc. | Transdermal contraceptive delivery system and process |
US7384650B2 (en) * | 1999-11-24 | 2008-06-10 | Agile Therapeutics, Inc. | Skin permeation enhancement composition for transdermal hormone delivery system |
US20020132801A1 (en) * | 2001-01-11 | 2002-09-19 | Schering Aktiengesellschaft | Drospirenone for hormone replacement therapy |
US20030124177A1 (en) * | 2000-04-26 | 2003-07-03 | Watson Pharmaceuticals, Inc. | Compositions and methods for transdermal oxybutynin therapy |
CN101305994A (en) | 2000-04-26 | 2008-11-19 | 沃特森药物公司 | Minimizing adverse experience associated with oxybutynin therapy |
US7179483B2 (en) * | 2000-04-26 | 2007-02-20 | Watson Pharmaceuticals, Inc. | Compositions and methods for transdermal oxybutynin therapy |
US7029694B2 (en) | 2000-04-26 | 2006-04-18 | Watson Laboratories, Inc. | Compositions and methods for transdermal oxybutynin therapy |
US20020119187A1 (en) * | 2000-09-29 | 2002-08-29 | Cantor Adam S. | Composition for the transdermal delivery of fentanyl |
MXPA03008349A (en) * | 2001-03-16 | 2004-10-15 | Johnson & Johnson | Transdermal patch for administering fentanyl. |
US20050208117A1 (en) * | 2001-03-16 | 2005-09-22 | Venkatraman Subramanian S | Transdermal administration of fentanyl and analogs thereof |
CN1536986B (en) * | 2001-03-27 | 2012-07-04 | 沃纳奇尔科特(爱尔兰)有限公司 | Intravaginal drug delivery devices for administration of antimicrobial agent |
JP2005508888A (en) * | 2001-08-14 | 2005-04-07 | バイオティ セラピーズ コーポレイション | How to treat alcoholism or alcoholism |
US7921999B1 (en) * | 2001-12-20 | 2011-04-12 | Watson Laboratories, Inc. | Peelable pouch for transdermal patch and method for packaging |
US20040033253A1 (en) * | 2002-02-19 | 2004-02-19 | Ihor Shevchuk | Acyl opioid antagonists |
KR101407131B1 (en) * | 2002-06-10 | 2014-06-19 | 유로-셀티크 소시에떼 아노뉨 | Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein |
JP4642467B2 (en) * | 2002-08-20 | 2011-03-02 | ユーロ−セルティーク エス.エイ. | Transdermal dosage form containing active agent and salt and free base form of side effect substance |
US20040062794A1 (en) * | 2002-09-30 | 2004-04-01 | Lee Shulman | 17Beta- estradiol/levonorgestrel transdermal patch for hormone replacement therapy |
DE10251256A1 (en) * | 2002-11-04 | 2004-05-13 | Novosis Ag | Transdermal drug delivery system for oxybutynin |
US20040258742A1 (en) * | 2003-04-11 | 2004-12-23 | Van Osdol William Woodson | Transdermal administration of N-(2,5-disubstituted phenyl)-N'-(3-substituted phenyl)-N'-methyl guanidines |
US20080020028A1 (en) * | 2003-08-20 | 2008-01-24 | Euro-Celtique S.A. | Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent |
PL1684782T3 (en) | 2003-10-03 | 2016-03-31 | Thorn Bioscience Llc | Process for the synchronization of ovulation for timed breeding without heat detection |
US7105263B2 (en) * | 2003-12-30 | 2006-09-12 | Samsung Electronics Company | Dry toner comprising encapsulated pigment, methods and uses |
US20060004094A1 (en) | 2004-07-02 | 2006-01-05 | Agisim Gary R | Composition and method for treating hemorrhoids and/or anorectal disorders |
US20060008432A1 (en) * | 2004-07-07 | 2006-01-12 | Sebastiano Scarampi | Gilsonite derived pharmaceutical delivery compositions and methods: nail applications |
US8252319B2 (en) | 2004-10-21 | 2012-08-28 | Durect Corporation | Transdermal delivery system for sufentanil |
SI1814531T1 (en) | 2004-10-21 | 2010-10-29 | Durect Corp | Transdermal delivery systems |
US8535709B2 (en) * | 2004-12-13 | 2013-09-17 | Southeastern Medical Technologies, Llc | Agents for controlling biological fluids and methods of use thereof |
US20070059350A1 (en) * | 2004-12-13 | 2007-03-15 | Kennedy John P | Agents for controlling biological fluids and methods of use thereof |
US20060127437A1 (en) * | 2004-12-13 | 2006-06-15 | Misty Anderson Kennedy | Semisolid system and combination semisolid, multiparticulate system for sealing tissues and/or controlling biological fluids |
WO2007011763A2 (en) * | 2005-07-15 | 2007-01-25 | 3M Innovative Properties Company | Adhesive sheet and methods of use thereof |
WO2007035941A2 (en) * | 2005-09-23 | 2007-03-29 | Alza Corporation | Transdermal galantamine delivery system |
WO2007035940A2 (en) * | 2005-09-23 | 2007-03-29 | Alza Corporation | Transdermal norelgestromin delivery system |
EP2308480B1 (en) | 2005-09-23 | 2014-08-13 | ALZA Corporation | High Enhancer-Loading Polyacrylate Formulation for Transdermal Applications |
US10010494B2 (en) | 2005-10-19 | 2018-07-03 | Menni Menashe Zinger | Methods for the treatment of hyperhidrosis |
CA2575398C (en) * | 2006-02-02 | 2011-12-20 | Omp, Inc. | Methods of treating skin to enhance therapeutic treatment thereof |
CA2642338A1 (en) * | 2006-02-13 | 2007-08-23 | Aveva Drug Delivery Systems | Adhesive preparation comprising sufentanil and methods of using the same |
US20070197435A1 (en) * | 2006-02-17 | 2007-08-23 | Webel Stephen K | Process for the synchronization of ovulation for timed breeding without heat detection |
NZ584190A (en) * | 2007-10-15 | 2012-09-28 | Alza Corp | Once-a-day replacement transdermal administration of fentanyl |
US20090175810A1 (en) | 2008-01-03 | 2009-07-09 | Gareth Winckle | Compositions and methods for treating diseases of the nail |
BRPI1014362A2 (en) | 2009-04-23 | 2016-04-05 | Pennatek Llc | method and composition to synchronize insemination time |
US8920392B2 (en) | 2009-05-05 | 2014-12-30 | Watson Laboratories, Inc. | Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions |
DE102009022915A1 (en) * | 2009-05-27 | 2010-12-09 | Lts Lohmann Therapie-Systeme Ag | Transdermal therapeutic system with controlled drug flux |
US8039494B1 (en) | 2010-07-08 | 2011-10-18 | Dow Pharmaceutical Sciences, Inc. | Compositions and methods for treating diseases of the nail |
US9950952B2 (en) | 2010-11-30 | 2018-04-24 | Schlumberger Technology Corporation | Methods for servicing subterranean wells |
US9834719B2 (en) * | 2010-11-30 | 2017-12-05 | Schlumberger Technology Corporation | Methods for servicing subterranean wells |
HUE055562T2 (en) | 2011-11-23 | 2021-11-29 | Therapeuticsmd Inc | Natural combination hormone replacement formulations and therapies |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
CA2892762C (en) | 2012-11-28 | 2022-07-19 | Jbs United Animal Health Ii Llc | Method for synchronizing time of insemination in gilts |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US20160228456A1 (en) * | 2013-10-01 | 2016-08-11 | Novartis Ag | Combination |
MX363386B (en) | 2013-10-03 | 2019-03-20 | Dow Pharmaceutical Sciences | Stabilized efinaconazole compositions. |
KR102612453B1 (en) | 2013-11-22 | 2023-12-08 | 다우 파마슈티컬 사이언시즈, 인코포레이티드 | Anti-infective methods, compositions, and devices |
EP3145489A1 (en) | 2014-05-22 | 2017-03-29 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
AU2015296609A1 (en) | 2014-07-29 | 2016-12-22 | Therapeuticsmd, Inc. | Transdermal cream |
US10149828B2 (en) | 2015-01-09 | 2018-12-11 | Chase Pharmaceuticals Corporation | Oxybutynin transdermal therapeutic system combination |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
BR112018070199A2 (en) | 2016-04-01 | 2019-01-29 | Therapeuticsmd Inc | pharmaceutical composition of steroid hormone |
CN109803649B (en) * | 2016-10-11 | 2022-10-21 | 久光制药株式会社 | Transdermal absorption preparation containing oxybutynin |
US20200330371A1 (en) | 2017-10-30 | 2020-10-22 | Teikoku Seiyaku Co., Ltd. | Transdermally administrable preparation |
EP3705136A4 (en) * | 2017-10-30 | 2021-08-18 | Kaken Pharmaceutical Co., Ltd. | External preparation for treating trichophytosis unguium |
USD933219S1 (en) | 2018-07-13 | 2021-10-12 | Intarcia Therapeutics, Inc. | Implant removal tool and assembly |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0295411A1 (en) * | 1987-05-15 | 1988-12-21 | Sansho Co., Ltd. | Pharmaceutical preparation for percutaneous administration containing eperisone or tolperisone or a salt thereof |
EP0368339A2 (en) * | 1988-11-11 | 1990-05-16 | Eisai Co., Ltd. | Pharmaceutical preparation for percutaneous administration containing bunazosin or its salt |
EP0431942A2 (en) * | 1989-12-06 | 1991-06-12 | Sansho Co., Ltd. | Percutaneously absorbable pharmaceutical preparation containing dopamine derivative |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3527864A (en) * | 1966-11-18 | 1970-09-08 | Procter & Gamble | Compositions for topical application to animal tissue and method of enhancing penetration thereof |
US3551554A (en) * | 1968-08-16 | 1970-12-29 | Crown Zellerbach Corp | Enhancing tissue penetration of physiologically active agents with dmso |
US4116956A (en) * | 1968-11-05 | 1978-09-26 | Takeda Chemical Industries, Ltd. | Benzodiazepine derivatives |
US3472931A (en) * | 1969-01-17 | 1969-10-14 | Foster Milburn Co | Percutaneous absorption with lower alkyl amides |
US3987052A (en) * | 1969-03-17 | 1976-10-19 | The Upjohn Company | 6-Phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines |
US3598123A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3797494A (en) * | 1969-04-01 | 1974-03-19 | Alza Corp | Bandage for the administration of drug by controlled metering through microporous materials |
US3598122A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3731683A (en) * | 1971-06-04 | 1973-05-08 | Alza Corp | Bandage for the controlled metering of topical drugs to the skin |
US3903256A (en) * | 1972-02-07 | 1975-09-02 | Procter & Gamble | Compositions for topical application of animal tissue and method of enhancing penetration thereof |
US3896238A (en) * | 1972-04-05 | 1975-07-22 | Procter & Gamble | Dermatological compositions |
US3952099A (en) * | 1973-03-13 | 1976-04-20 | The Procter & Gamble Company | Dermatological compositions |
US4006218A (en) * | 1974-07-08 | 1977-02-01 | Johnson & Johnson | Potentiated medicaments |
US4046886A (en) * | 1975-01-17 | 1977-09-06 | The Procter & Gamble Company | Dermatological compositions |
US4144317A (en) * | 1975-05-30 | 1979-03-13 | Alza Corporation | Device consisting of copolymer having acetoxy groups for delivering drugs |
US4405616A (en) * | 1975-06-19 | 1983-09-20 | Nelson Research & Development Company | Penetration enhancers for transdermal drug delivery of systemic agents |
US4031894A (en) * | 1975-12-08 | 1977-06-28 | Alza Corporation | Bandage for transdermally administering scopolamine to prevent nausea |
US4130667A (en) * | 1976-01-12 | 1978-12-19 | The Procter & Gamble Company | Dermatological compositions |
US4335115A (en) * | 1976-11-01 | 1982-06-15 | The Procter & Gamble Company | Anti-acne composition |
US4201211A (en) * | 1977-07-12 | 1980-05-06 | Alza Corporation | Therapeutic system for administering clonidine transdermally |
US4299826A (en) * | 1979-10-12 | 1981-11-10 | The Procter & Gamble Company | Anti-acne composition |
US4286592A (en) * | 1980-02-04 | 1981-09-01 | Alza Corporation | Therapeutic system for administering drugs to the skin |
US4314557A (en) * | 1980-05-19 | 1982-02-09 | Alza Corporation | Dissolution controlled active agent dispenser |
US4379454A (en) * | 1981-02-17 | 1983-04-12 | Alza Corporation | Dosage for coadministering drug and percutaneous absorption enhancer |
US4464378A (en) * | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
US4343798A (en) * | 1981-06-23 | 1982-08-10 | The Procter & Gamble Company | Topical antimicrobial anti-inflammatory compositions |
US4849226A (en) * | 1981-06-29 | 1989-07-18 | Alza Corporation | Method for increasing oxygen supply by administering vasodilator |
US4440777A (en) * | 1981-07-07 | 1984-04-03 | Merck & Co., Inc. | Use of eucalyptol for enhancing skin permeation of bio-affecting agents |
US4435180A (en) * | 1982-05-25 | 1984-03-06 | Alza Corporation | Elastomeric active agent delivery system and method of use |
US4468391A (en) * | 1982-06-25 | 1984-08-28 | Ayerst, Mckenna & Harrison, Inc. | Combination of β-adrenoceptor antagonists and anxiolytic agents |
US4508726A (en) * | 1982-09-16 | 1985-04-02 | The Upjohn Company | Treatment of panic disorders with alprazolam |
US4559222A (en) * | 1983-05-04 | 1985-12-17 | Alza Corporation | Matrix composition for transdermal therapeutic system |
US4710497A (en) * | 1983-05-20 | 1987-12-01 | Nitto Electric Industrial Co., Ltd. | Method for percutaneously administering physiologically active agents |
US4552872A (en) * | 1983-06-21 | 1985-11-12 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing corticosteroids |
US4537776A (en) * | 1983-06-21 | 1985-08-27 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone |
US4557934A (en) * | 1983-06-21 | 1985-12-10 | The Procter & Gamble Company | Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one |
US4590190A (en) * | 1983-07-01 | 1986-05-20 | Nitto Electric Industrial Co., Ltd. | Method for percutaneously administering physiologically active agents using an alcohol adjuvant and a solvent |
US4752612A (en) * | 1983-07-01 | 1988-06-21 | Nitto Electrical Industrial Co., Ltd. | Method and percutaneously administering physiologically active agents using an alcohol adjuvant and a solvent |
US4588721A (en) * | 1983-09-12 | 1986-05-13 | The Upjohn Company | Treatment of negative symptoms of schizophrenia |
US4933184A (en) * | 1983-12-22 | 1990-06-12 | American Home Products Corp. (Del) | Menthol enhancement of transdermal drug delivery |
US4588739A (en) * | 1984-03-02 | 1986-05-13 | Research Foundation For Mental Hygiene, Inc. | Method of preventing withdrawal symptoms associated with the cessation or reduction of tobacco smoking |
US4783456A (en) * | 1984-03-02 | 1988-11-08 | Research Foundation For Mental Hygiene, Inc. | Method of preventing withdrawal symptoms associated with the cessation or reduction of tobacco smoking |
US4683231A (en) * | 1984-03-02 | 1987-07-28 | Research Foundation For Mental Hygiene, Inc. | Method of preventing withdrawal symptoms associated with the cessation or reduction of tobacco smoking |
US4968507A (en) * | 1984-06-20 | 1990-11-06 | Merck & Co., Inc. | Controlled porosity osmotic pump |
US4851228A (en) * | 1984-06-20 | 1989-07-25 | Merck & Co., Inc. | Multiparticulate controlled porosity osmotic |
US4704282A (en) * | 1984-06-29 | 1987-11-03 | Alza Corporation | Transdermal therapeutic system having improved delivery characteristics |
US4588580B2 (en) * | 1984-07-23 | 1999-02-16 | Alaz Corp | Transdermal administration of fentanyl and device therefor |
US4721709A (en) * | 1984-07-26 | 1988-01-26 | Pyare Seth | Novel pharmaceutical compositions containing hydrophobic practically water-insoluble drugs adsorbed on pharmaceutical excipients as carrier; process for their preparation and the use of said compositions |
US4626539A (en) * | 1984-08-10 | 1986-12-02 | E. I. Dupont De Nemours And Company | Trandermal delivery of opioids |
US4573995A (en) * | 1984-10-09 | 1986-03-04 | Alza Corporation | Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine |
US4568343A (en) * | 1984-10-09 | 1986-02-04 | Alza Corporation | Skin permeation enhancer compositions |
US4806341A (en) * | 1985-02-25 | 1989-02-21 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration |
US4663454A (en) * | 1985-04-17 | 1987-05-05 | The Upjohn Company | Process to prepare α-chloroalprazolam |
US4645502A (en) * | 1985-05-03 | 1987-02-24 | Alza Corporation | Transdermal delivery of highly ionized fat insoluble drugs |
US4685913A (en) * | 1985-05-24 | 1987-08-11 | Professional Care Products, Inc. | External single-use catheter |
JPS61293911A (en) * | 1985-06-24 | 1986-12-24 | Teisan Seiyaku Kk | Sustained release preparation |
US4666903A (en) * | 1985-08-13 | 1987-05-19 | Yale University | Novel use of benzodiazepine antagonist |
US4595684A (en) * | 1985-08-16 | 1986-06-17 | Ciba-Geigy Corporation | Method of suppressing benzodiazepine induced sedation with 2-(p-methoxypenyl)-pyrazolo[4,3-c]quinolin-3(5H)-one or a salt thereof |
US4634703A (en) * | 1985-10-25 | 1987-01-06 | Bristol-Myers Company | Method for alleviation of panic disorders |
JP2573275B2 (en) * | 1986-03-10 | 1997-01-22 | ブルグハルト,クルト | Pharmaceutical preparations and methods for their production |
US4908389A (en) * | 1986-08-27 | 1990-03-13 | Warner-Lambert Company | Penetration enhancement system |
US4908027A (en) * | 1986-09-12 | 1990-03-13 | Alza Corporation | Subsaturated transdermal therapeutic system having improved release characteristics |
US4863970A (en) * | 1986-11-14 | 1989-09-05 | Theratech, Inc. | Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols |
US4876249A (en) * | 1987-01-12 | 1989-10-24 | Rajadhyaksha Vithal J | Compositions and method comprising heterocyclic compounds containing two heteroatoms |
US4746515A (en) * | 1987-02-26 | 1988-05-24 | Alza Corporation | Skin permeation enhancer compositions using glycerol monolaurate |
US4816258A (en) * | 1987-02-26 | 1989-03-28 | Alza Corporation | Transdermal contraceptive formulations |
US4788062A (en) * | 1987-02-26 | 1988-11-29 | Alza Corporation | Transdermal administration of progesterone, estradiol esters, and mixtures thereof |
US4940586A (en) * | 1987-02-26 | 1990-07-10 | Alza Corporation | Skin permeation enhancer compositions using sucrose esters |
CH674618A5 (en) * | 1987-04-02 | 1990-06-29 | Ciba Geigy Ag | |
US4783450A (en) * | 1987-04-13 | 1988-11-08 | Warner-Lambert Company | Use of commercial lecithin as skin penetration enhancer |
US5017575A (en) * | 1987-06-09 | 1991-05-21 | Golwyn Daniel H | Treatment of immunologically based disorders, specifically Crohn's disease |
US4992445A (en) * | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US4795644A (en) * | 1987-08-03 | 1989-01-03 | Merck & Co., Inc. | Device for pH independent release of drugs through the Donnan-like influence of charged insoluble resins |
US4814183A (en) * | 1987-08-31 | 1989-03-21 | Merck & Co., Inc. | Device for the controlled release of drugs with Donnan-like modulation by charged insoluble resins |
US4820720A (en) * | 1987-08-24 | 1989-04-11 | Alza Corporation | Transdermal drug composition with dual permeation enhancers |
US5256421A (en) * | 1987-09-24 | 1993-10-26 | Jencap Research Ltd. | Hormone preparation and method |
US5108995A (en) * | 1987-09-24 | 1992-04-28 | Jencap Research Ltd. | Hormone preparation and method |
US5276022A (en) * | 1987-09-24 | 1994-01-04 | Jencap Research Ltd. | Hormone preparation and method |
US4943435A (en) * | 1987-10-05 | 1990-07-24 | Pharmetrix Corporation | Prolonged activity nicotine patch |
US4863738A (en) * | 1987-11-23 | 1989-09-05 | Alza Corporation | Skin permeation enhancer compositions using glycerol monooleate |
GB8728294D0 (en) * | 1987-12-03 | 1988-01-06 | Reckitt & Colmann Prod Ltd | Treatment compositions |
US4925844A (en) * | 1988-02-09 | 1990-05-15 | Ici Americas Inc. | Antagonizing the pharmacological effects of a benzodiazepine receptor agonist |
US4994278A (en) * | 1988-03-04 | 1991-02-19 | Noven Pharmaceuticals, Inc. | Breathable backing |
US5004610A (en) * | 1988-06-14 | 1991-04-02 | Alza Corporation | Subsaturated nicotine transdermal therapeutic system |
CA2002299A1 (en) | 1988-11-10 | 1990-05-10 | Eugene G. Drust | Compositions for the transdermal delivery of buprenorphine salts |
US4981468A (en) * | 1989-02-17 | 1991-01-01 | Eli Lilly And Company | Delivery device for orally administered therapeutic agents |
US5246949A (en) * | 1989-12-06 | 1993-09-21 | Sansho Co., Ltd. | Preparation for endermism containing dopamine derivatives |
US5252588A (en) * | 1990-04-27 | 1993-10-12 | Sekisui Kagaku Kogyo Kabushiki Kaisha | Percutaneously absorbable crosslinked polyvinylpyrrolidone eperisone or tolperisone preparation |
US5314694A (en) * | 1990-10-29 | 1994-05-24 | Alza Corporation | Transdermal formulations, methods and devices |
US5198223A (en) * | 1990-10-29 | 1993-03-30 | Alza Corporation | Transdermal formulations, methods and devices |
US5122382A (en) * | 1990-10-29 | 1992-06-16 | Alza Corporation | Transdermal contraceptive formulations, methods and devices |
US5122383A (en) * | 1991-05-17 | 1992-06-16 | Theratech, Inc. | Sorbitan esters as skin permeation enhancers |
US5211952A (en) * | 1991-04-12 | 1993-05-18 | University Of Southern California | Contraceptive methods and formulations for use therein |
PT100502A (en) * | 1991-05-20 | 1993-08-31 | Alza Corp | PHARMACEUTICAL COMPOSITIONS FOR INCREASING THE CAPACITY OF PERMEACAO IN THE SKIN USING GLYCEROL MONOLINOLEATE |
US5149538A (en) * | 1991-06-14 | 1992-09-22 | Warner-Lambert Company | Misuse-resistive transdermal opioid dosage form |
MX9302812A (en) * | 1992-05-13 | 1993-11-01 | Alza Corp | TRANSDERMIC ADMINISTRATION OF OXYBUTININE. |
CA2165802A1 (en) * | 1993-09-29 | 1995-04-06 | Eun Soo Lee | Monoglyceride/lactate ester permeation enhancer for oxybutynin |
-
1994
- 1994-09-29 CA CA002165802A patent/CA2165802A1/en not_active Abandoned
- 1994-09-29 WO PCT/US1994/011226 patent/WO1995009007A1/en not_active Application Discontinuation
- 1994-09-29 EP EP94930573A patent/EP0721349A1/en not_active Ceased
- 1994-09-29 KR KR1019960701610A patent/KR960704578A/en not_active Application Discontinuation
- 1994-09-29 NZ NZ274711A patent/NZ274711A/en unknown
- 1994-09-29 US US08/637,678 patent/US5750137A/en not_active Expired - Lifetime
- 1994-09-29 WO PCT/US1994/011120 patent/WO1995009006A1/en active IP Right Grant
- 1994-09-29 CA CA002167526A patent/CA2167526A1/en not_active Abandoned
- 1994-09-29 EP EP94929976A patent/EP0721348B1/en not_active Expired - Lifetime
- 1994-09-29 DE DE69420419T patent/DE69420419T2/en not_active Expired - Fee Related
- 1994-09-29 JP JP51047695A patent/JP3688293B2/en not_active Expired - Fee Related
- 1994-09-29 US US08/617,763 patent/US5747065A/en not_active Expired - Lifetime
- 1994-09-29 AT AT94929976T patent/ATE183926T1/en not_active IP Right Cessation
- 1994-09-29 JP JP51048695A patent/JP3792252B2/en not_active Expired - Fee Related
- 1994-09-29 AU AU79647/94A patent/AU679794B2/en not_active Ceased
- 1994-09-29 KR KR1019960701611A patent/KR960704579A/en not_active Application Discontinuation
- 1994-09-29 NZ NZ275615A patent/NZ275615A/en unknown
- 1994-09-29 AU AU79249/94A patent/AU679793B2/en not_active Ceased
-
1995
- 1995-03-09 US US08/401,593 patent/US5686097A/en not_active Expired - Lifetime
-
2005
- 2005-12-05 JP JP2005350255A patent/JP2006117688A/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0295411A1 (en) * | 1987-05-15 | 1988-12-21 | Sansho Co., Ltd. | Pharmaceutical preparation for percutaneous administration containing eperisone or tolperisone or a salt thereof |
EP0368339A2 (en) * | 1988-11-11 | 1990-05-16 | Eisai Co., Ltd. | Pharmaceutical preparation for percutaneous administration containing bunazosin or its salt |
EP0431942A2 (en) * | 1989-12-06 | 1991-06-12 | Sansho Co., Ltd. | Percutaneously absorbable pharmaceutical preparation containing dopamine derivative |
Cited By (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996010429A3 (en) * | 1994-09-29 | 1996-07-25 | Alza Corp | Improved transdermal device having decreased delamination |
WO1996010429A2 (en) * | 1994-09-29 | 1996-04-11 | Alza Corporation | Improved transdermal device having decreased delamination |
US5614211A (en) * | 1994-09-29 | 1997-03-25 | Alza Corporation | Oxybutynin transdermal device having decreased delamination |
US5882676A (en) * | 1995-05-26 | 1999-03-16 | Alza Corporation | Skin permeation enhancer compositions using acyl lactylates |
WO1996037231A1 (en) * | 1995-05-26 | 1996-11-28 | Alza Corporation | Skin permeation enhancer compositions using acyl lactylates |
CN1107522C (en) * | 1995-05-26 | 2003-05-07 | 阿尔萨公司 | Skin permeation enhancer compositions using acyl lactylates |
JPH11505843A (en) * | 1995-05-26 | 1999-05-25 | アルザ コーポレイション | Skin permeation enhancer compositions using acyl lactylate compounds |
US5785991A (en) * | 1995-06-07 | 1998-07-28 | Alza Corporation | Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate |
WO1996040259A3 (en) * | 1995-06-07 | 1997-02-27 | Alza Corp | Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate |
WO1996040259A2 (en) * | 1995-06-07 | 1996-12-19 | Alza Corporation | Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate |
FR2735027A1 (en) * | 1995-06-07 | 1996-12-13 | Alza Corp | Compsns. for acceleration of transdermal passage of active materials |
AU714809B2 (en) * | 1995-06-07 | 2000-01-13 | Alza Corporation | Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate |
KR100524325B1 (en) * | 1995-06-07 | 2006-01-27 | 앨자 코포레이션 | Skin Permeation Enhancer compositions Comprising Glycerol Monolaurate and Lauryl Acetate |
US5843468A (en) * | 1995-06-07 | 1998-12-01 | Alza Corporation | Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate |
WO1997024148A1 (en) * | 1995-12-29 | 1997-07-10 | Cygnus, Inc. | Systems and methods for the transdermal administration of androgenic agents |
WO1997039743A1 (en) * | 1996-04-24 | 1997-10-30 | Rutgers, The State University Of New Jersey | Transdermal contraceptive delivery system |
US6007837A (en) * | 1996-07-03 | 1999-12-28 | Alza Corporation | Drug delivery devices and process of manufacture |
WO1998000118A3 (en) * | 1996-07-03 | 1998-03-05 | Alza Corp | Drug delivery devices and process of manufacture |
WO1998000118A2 (en) * | 1996-07-03 | 1998-01-08 | Alza Corporation | Drug delivery devices and process of manufacture |
US7011844B2 (en) | 1996-07-15 | 2006-03-14 | Alza Corporation | Formulations for the administration of fluoxetine |
US6512010B1 (en) | 1996-07-15 | 2003-01-28 | Alza Corporation | Formulations for the administration of fluoxetine |
WO1998010770A1 (en) * | 1996-09-11 | 1998-03-19 | Tillotts Pharma Ag | Oral compositions containing fluocinonide |
US6004578A (en) * | 1996-10-24 | 1999-12-21 | Alza Corporation | Permeation enhances for transdermal drug delivery compositions, devices and methods |
US6203817B1 (en) | 1997-02-19 | 2001-03-20 | Alza Corporation | Reduction of skin reactions caused by transdermal drug delivery |
US6174545B1 (en) | 1997-07-01 | 2001-01-16 | Alza Corporation | Drug delivery devices and process of manufacture |
US5925629A (en) * | 1997-10-28 | 1999-07-20 | Vivus, Incorporated | Transurethral administration of androgenic agents for the treatment of erectile dysfunction |
US6267984B1 (en) | 1997-12-22 | 2001-07-31 | Alza Corporation | Skin permeation enhancer compositions comprising a monoglyceride and ethyl palmitate |
US6960353B2 (en) | 1998-07-24 | 2005-11-01 | Alza Corporation | Formulations for the transdermal administration of fenoldopam |
EP1666026B2 (en) † | 1999-02-08 | 2015-02-25 | Intarcia Therapeutics, Inc | Non-aqueous single phase biocompatible viscous vehicles and methods for preparing the same |
US8992961B2 (en) | 1999-02-08 | 2015-03-31 | Intarcia Therapeutics, Inc. | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
US9724293B2 (en) | 2003-11-17 | 2017-08-08 | Intarcia Therapeutics, Inc. | Methods of manufacturing viscous liquid pharmaceutical formulations |
US9682127B2 (en) | 2005-02-03 | 2017-06-20 | Intarcia Therapeutics, Inc. | Osmotic delivery device comprising an insulinotropic peptide and uses thereof |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
US10363287B2 (en) | 2005-02-03 | 2019-07-30 | Intarcia Therapeutics, Inc. | Method of manufacturing an osmotic delivery device |
US9526763B2 (en) | 2005-02-03 | 2016-12-27 | Intarcia Therapeutics Inc. | Solvent/polymer solutions as suspension vehicles |
US9539200B2 (en) | 2005-02-03 | 2017-01-10 | Intarcia Therapeutics Inc. | Two-piece, internal-channel osmotic delivery system flow modulator |
US10527170B2 (en) | 2006-08-09 | 2020-01-07 | Intarcia Therapeutics, Inc. | Osmotic delivery systems and piston assemblies for use therein |
US9572889B2 (en) | 2008-02-13 | 2017-02-21 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
US10441528B2 (en) | 2008-02-13 | 2019-10-15 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
US10869830B2 (en) | 2009-09-28 | 2020-12-22 | Intarcia Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
US10231923B2 (en) | 2009-09-28 | 2019-03-19 | Intarcia Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
US10159714B2 (en) | 2011-02-16 | 2018-12-25 | Intarcia Therapeutics, Inc. | Compositions, devices and methods of use thereof for the treatment of cancers |
US11090186B2 (en) | 2011-07-11 | 2021-08-17 | Medicines360 | Methods for using intrauterine systems and IUD insertion devices |
US10028858B2 (en) | 2011-07-11 | 2018-07-24 | Medicines360 | Intrauterine systems, IUD insertion devices, and related methods and kits therefor |
US9006462B2 (en) | 2013-02-28 | 2015-04-14 | Dermira, Inc. | Glycopyrrolate salts |
US9006461B2 (en) | 2013-02-28 | 2015-04-14 | Dermira, Inc. | Crystalline glycopyrrolate tosylate |
US11291652B2 (en) | 2013-02-28 | 2022-04-05 | Journey Medical Corporation | Glycopyrrolate salts |
US11291651B2 (en) | 2013-02-28 | 2022-04-05 | Journey Medical Corporation | Glycopyrrolate salts |
US10004717B2 (en) | 2013-02-28 | 2018-06-26 | Dermira, Inc. | Glycopyrrolate salts |
US9259414B2 (en) | 2013-02-28 | 2016-02-16 | Dermira, Inc. | Glycopyrrolate salts |
US9610278B2 (en) | 2013-02-28 | 2017-04-04 | Dermira, Inc. | Glycopyrrolate salts |
US10543192B2 (en) | 2013-02-28 | 2020-01-28 | Dermira, Inc. | Glycopyrrolate salts |
US10548875B2 (en) | 2013-02-28 | 2020-02-04 | Dermira, Inc. | Glycopyrrolate salts |
US10583080B2 (en) | 2014-09-30 | 2020-03-10 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
US10925639B2 (en) | 2015-06-03 | 2021-02-23 | Intarcia Therapeutics, Inc. | Implant placement and removal systems |
US11214607B2 (en) | 2016-05-16 | 2022-01-04 | Intarcia Therapeutics Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
US10501517B2 (en) | 2016-05-16 | 2019-12-10 | Intarcia Therapeutics, Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
US11840559B2 (en) | 2016-05-16 | 2023-12-12 | I2O Therapeutics, Inc. | Glucagon-receptor selective polypeptides and methods of use thereof |
USD912249S1 (en) | 2016-06-02 | 2021-03-02 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD835783S1 (en) | 2016-06-02 | 2018-12-11 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD962433S1 (en) | 2016-06-02 | 2022-08-30 | Intarcia Therapeutics, Inc. | Implant placement guide |
US10835580B2 (en) | 2017-01-03 | 2020-11-17 | Intarcia Therapeutics, Inc. | Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug |
US11654183B2 (en) | 2017-01-03 | 2023-05-23 | Intarcia Therapeutics, Inc. | Methods comprising continuous administration of exenatide and co-administration of a drug |
Also Published As
Publication number | Publication date |
---|---|
CA2165802A1 (en) | 1995-04-06 |
JPH09505278A (en) | 1997-05-27 |
AU679794B2 (en) | 1997-07-10 |
NZ275615A (en) | 1996-11-26 |
EP0721348A1 (en) | 1996-07-17 |
KR960704578A (en) | 1996-10-09 |
DE69420419D1 (en) | 1999-10-07 |
WO1995009007A1 (en) | 1995-04-06 |
JP3792252B2 (en) | 2006-07-05 |
CA2167526A1 (en) | 1995-04-06 |
AU679793B2 (en) | 1997-07-10 |
JP3688293B2 (en) | 2005-08-24 |
US5750137A (en) | 1998-05-12 |
ATE183926T1 (en) | 1999-09-15 |
NZ274711A (en) | 1996-11-26 |
AU7924994A (en) | 1995-04-18 |
EP0721349A1 (en) | 1996-07-17 |
DE69420419T2 (en) | 1999-12-23 |
JP2006117688A (en) | 2006-05-11 |
EP0721348B1 (en) | 1999-09-01 |
US5686097A (en) | 1997-11-11 |
JPH09505279A (en) | 1997-05-27 |
US5747065A (en) | 1998-05-05 |
AU7964794A (en) | 1995-04-18 |
KR960704579A (en) | 1996-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU679793B2 (en) | Monoglyceride/lactate ester permeation enhancer | |
EP0783341B1 (en) | Improved transdermal device having decreased delamination | |
AU697200B2 (en) | Skin permeation enhancer compositions using acyl lactylates | |
US5785991A (en) | Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate | |
US6267984B1 (en) | Skin permeation enhancer compositions comprising a monoglyceride and ethyl palmitate | |
US5641504A (en) | Skin permeation enhancer compositions using glycerol monolinoleate | |
WO1992020377A1 (en) | Skin permeation enhancer compositions using glycerol monolinoleate | |
PH27001A (en) | Transdermal monolith system | |
WO1994021262A1 (en) | Device for the transdermal administration of alprazolam | |
FR2735027A1 (en) | Compsns. for acceleration of transdermal passage of active materials | |
IE921615A1 (en) | Skin permeation enhancer compositions using glycerol¹monolinoleate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA FI JP KR NO NZ US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 274711 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994929976 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2167526 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08637678 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1994929976 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1994929976 Country of ref document: EP |